Immunotherapy as Second-line Treatment in Grade 3 Neuroendocrine Carcinomas: A Prospective Case Series from an ENETS Center of Excellence

#2875

Introduction: Metastatic WHO grade 3 extra-pulmonary neuroendocrine carcinomas (EP-NEC) have a poor prognosis and optimal treatment after first-line platinum-etoposide chemotherapy remains unclear. A recent, small phase II study combining ipilimumab and nivolumab showed promising results

Aim(s): Evaluation of immunotherapy in NETwerk, an ENETS Center of Excellence, as new treatment option in EP-NEC

Materials and methods: Patient characteristics of all EP-NEC, discussed at the NET-specific MDT (NET MDT), were prospectively recorded between August 2018 and November 2019. Progression-free survival (PFS) of patients receiving immunotherapy was calculated

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Vandamme T, De Backer L, Van den Brande J, Op de Beeck B, Driessen A,

Keywords: NEC, immunotherapy,